ISEE — IVERIC bio Share News
0.000.00%
Last trade - 00:00HealthcareAdventurousLarge Cap
Analysis: Amgen's antitrust woes spur wider pharmaceutical deal fears
Iveric Bio Inc Reports Results For The Quarter Ended In March: Earnings Summary
The end of cheap credit could hurry Japanese M&A
U.S. STOCKS ON THE MOVE-US banks, Biomea Fusion, Tutor Perini
U.S. STOCKS ON THE MOVE-Minerva Neurosciences, Midwest Holding, Global Payments
Iveric Bio soars on Astellas' $5.9 bln buyout deal
U.S. STOCKS ON THE MOVE-Norwegian Cruise Line, Marker Therapeutics, KBR
Brief: Iveric Bio Inc Says Upon Termination Of Merger, Co Will Be Required To Pay Astellas Us Holding, Inc. A Termination Fee Of $222.4 Million
U.S. STOCKS ON THE MOVE-First Republic Bank, Iveric Bio, Carvana
Iveric Bio soars after Astellas' $5.9 bln deal to buy co
Japan's Astellas Pharma agrees to buy IVERIC Bio for $5.9 bln (updated)
Astellas Pharma buys Iveric Bio for $5.9 bln
Brief: Astellas Enters Into Definitive Agreement To Acquire Iveric Bio
Iveric Bio Inc Expected To Post A Loss Of 47 Cents A Share: Earnings Preview
Brief: Iveric Bio - On March 14, Co Entered Into Commercial Manufacturing And Supply Agreement With Agilent Technologies
Brief: Iveric Bio Maintains Minimal Amount Of Cash & Cash Equivalents With Silicon Valley Bank
U.S. RESEARCH ROUNDUP-Axon Enterprise, Dorman Products, Verisk Analytics
U.S. STOCKS ON THE MOVE-First Solar, Iveric Bio, Salesforce
Iveric gains as study shows eye disorder drug helps cut potential vision loss